Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological, Endocrine, and Metabolic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OXT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OXT Prepropeptide / Mutant Protein & Wild-Type Analog Panel High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View OXT Products |
| Gene Delivery | OXT Promise-ORF / Lentivirus Full-length ORF for stable cell lines. HEK293 expressed. |
View OXT Products |
| Benchmark Ab | Anti-OXT Recombinant Antibody (Biosimilar-grade Reference) Recombinant positive control for PK/PD and biomarker assays. |
View OXT Products |
| Validator | OXT siRNA Set For knockdown verification and target engagement studies. |
View OXT Products |
| Related Target: OXTR | Oxytocin Receptor (OXTR) Cognate G-protein coupled receptor (GPCR) for target binding and functional assays. |
View OXTR Products |
| Related Target: AVP | Arginine Vasopressin (AVP) Structural homolog (2-AA difference); required for selectivity and off-target counter-screening. |
View AVP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Conformation Preservation | Lentivirus-mediated stable cell line construction for functional OXTR calcium flux assays. |
| Selectivity Screening (OXT vs AVP) | Homolog panel proteins (AVP, AVPRs) strictly verified by mass spectrometry and sequence analysis. |
| Cross-species PK/PD Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilar-grade) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks in cell-based screening. |
Live OXT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OXT therapeutics is intensifying, with major players shifting focus from traditional short-acting obstetrical peptides to long-acting analogs and intranasal formulations. As first-generation therapies for labor induction and postpartum hemorrhage remain standards of care, the next wave of R&D is targeting complex neuropsychiatric and metabolic conditions, including Autism Spectrum Disorder (ASD), Prader-Willi syndrome, migraines, and obesity. Achieving robust blood-brain barrier (BBB) penetration and preventing cross-reactivity with vasopressin receptors are the primary hurdles defining the next generation of OXT modulators. The emerging pipeline also emphasizes CNS-penetrant formulations and highly selective non-peptide modulators.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-Acting Peptide Analog | Ferring Pharmaceuticals, Tonix Pharmaceuticals, Acadia | Postpartum Hemorrhage, Migraine, Prader-Willi Syndrome | Stability & OXTR Binding; selectivity against AVP (need high-purity homologs) |
| Intranasal Formulation / Biologic | Novartis, OptiNose, Tractor Pharma, CNS-focused biotechs | Autism Spectrum Disorder, Social Cognition, PTSD, Neuropsychiatric Disorders | Receptor Binding (need OXTR Lentivirus for cells); Integrity & Purity QC (need high-purity endotoxin-controlled OXT antigen) |
| Small Molecule Modulator | Various Biotechs, Academic consortia | Schizophrenia, Anxiety, ASD, Social Cognition | Functional Screening (need sequence-verified targets); Selectivity Panel (need OXT/AVP ortholog proteins for counter-screening) |